Anne brings to 23andMe a 10-year background in
healthcare investing, focused primarily on biotechnology companies.
Anne left the investing world with the hope that she could have a
positive impact on the medical world and the biotechnology industry
through 23andMe. From her vantage point, Anne saw a need for creating a
way to generate more information—especially more personalized
information—so that biotech and pharmaceutical companies could b...
more
Anne brings to 23andMe a 10-year background in
healthcare investing, focused primarily on biotechnology companies.
Anne left the investing world with the hope that she could have a
positive impact on the medical world and the biotechnology industry
through 23andMe. From her vantage point, Anne saw a need for creating a
way to generate more information—especially more personalized
information—so that biotech and pharmaceutical companies could better
understand and develop new drugs and diagnostics. By encouraging
individuals to access and learn about their own genetic information,
23andMe will create a common, standardized resource that has the
potential to accelerate drug discovery and bring personalized medicine
to the public. (Plus, getting access to her own genetic information and
understanding it has always been one of Anne's ambitions.) Anne
graduated from Yale University with a B.S. in biology.
less
